# Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population

> **NCT02533973** · PHASE4 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 951 (actual)

## Conditions studied

- Psoriasis Vulgaris

## Interventions

- **DRUG:** Xamiol® gel
- **DRUG:** Daivonex® scalp solution

## Key facts

- **NCT ID:** NCT02533973
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2018-03-06
- **Final completion:** 2018-03-06
- **Target enrollment:** 951 (ACTUAL)
- **Last updated:** 2025-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02533973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02533973, "Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT02533973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*